Singapore-based startup Aevice Health secures additional funding to expand market presence

To accelerate the development and global rollout of respiratory health monitoring solutions

Aevice Health, a Singapore-based medtech company specialising in advanced respiratory health solutions, has secured an additional investment from Denka Co., Ltd., a global chemical company, through Pegasus Tech Ventures, along with Singapore-based Deep Tech venture capital firm Elev8.vc.

The funding will accelerate the development and global rollout of Aevice Health’s innovation respiratory health monitoring solutions.

“We look forward to collaborating closely with Denka and Elev8 to advance our technology and unlock greater value to healthcare professionals and patients” said Adrian Ang, CEO of Aevice Health.

“Through this investment, Denka aims to deepen our initiatives in the healthcare field, with a particular focus on prevention, diagnosis, and treatment”, said Hideki Toya, Managing Executive Officer of Denka Co., Ltd. “By integrating Aevice Health's AI-powered electronic stethoscope technology with our expertise in respiratory infectious diseases and immunology, we strive to further advance our efforts in digital health and address medical challenges. Additionally, Denka will engage in joint research and development of new AI technologies in the field of respiratory diseases and related disease areas.”

Aditya Mathur, MD of Elev8.vc said, “Their approach not only addresses an urgent need for better respiratory care but also demonstrates how remote monitoring can reshape the patient-clinician relationship."

Founded in 2018, Aevice Health has emerged as one of the leading players in respiratory health management with its flagship product, the AeviceMD, which has received regulatory approval in both Singapore and the United States. This smart wearable stethoscope provides remote home monitoring of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). By delivering actionable insights, it empowers both patients and clinicians to manage respiratory health more effectively.

The additional funding will enable Aevice Health to expand its market presence, strengthen its research and development efforts, and foster strategic partnerships with healthcare providers worldwide.

Published on : 20th January, 2025